Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient

被引：7
|
作者：
Ito, Munehiro [1 ]
Kanda, Shintaro [1 ]
Yoshida, Tatsuya [1 ]
Okuma, Yusuke [1 ]
Jo, Hitomi [1 ]
Fukuhara, Suguru [2 ]
Maeshima, Akiko Miyagi [3 ]
Ohe, Yuichiro [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Hematol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Dept Diagnost Pathol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan
来源：
LUNG CANCER | 2020年 / 146卷
关键词：
immune-related thrombocytopenia; pembrolizumab; eltrombopag olamine; rituximab; non-small cell lung cancer; PURPURA;
D O I：
10.1016/j.lungcan.2020.05.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objectives: Immune checkpoint inhibitors (ICIs) have shown antitumor activity against a wide variety of malignancies. ICI-induced immune-related thrombocytopenia is a rare immune-related adverse event (irAE). Little is known about the treatment of refractory immune-related thrombocytopenia in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab. Results: We report the case of a patient with advanced NSCLC complicated by pembrolizumab-induced refractory immune-related thrombocytopenia who showed remarkable improvement in the thrombocytopenia in response to eltrombopag olamine treatment. Conclusion: Eltrombopag olamine can be a viable treatment option for refractory pembrolizumab-induced immune-related thrombocytopenia in an NSCLC patient.
引用
收藏
页码：362 / 365
页数：4
相关论文
共 50 条
  • [21] PREDICTIVE BIOMARKERS OF SEVERE IMMUNE-RELATED ADVERSE EVENTS IN NON-SMALL CELL LUNG CANCER
    Magalhaes Ferreira, P.
    Serino, M.
    Freitas, C.
    Martins, M.
    Cardoso, C.
    Sousa, C.
    Santos, V.
    Araujo, D.
    Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    CHEST, 2022, 161 (06) : 311A - 311A
  • [22] Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient
    Matsumoto, Sachiko
    Watanabe, Keisuke
    Kobayashi, Nobuaki
    Irie, Kuniyasu
    Yamanaka, Shoji
    Kaneko, Takeshi
    RESPIROLOGY CASE REPORTS, 2020, 8 (05):
  • [23] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
    Haratani, Koji
    Hayashi, Hidetoshi
    Chiba, Yasutaka
    Kudo, Keita
    Yonesaka, Kimio
    Kato, Ryoji
    Kaneda, Hiroyasu
    Hasegawa, Yoshikazu
    Tanaka, Kaoru
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    JAMA ONCOLOGY, 2018, 4 (03) : 374 - 378
  • [24] Delayed onset immune related adverse effects (IRAEs) of pembrolizumab in non-small cell lung cancer
    Yan, H.
    Jiang, Y.
    Luong, M. K.
    Naban, N.
    Kane, C.
    Conibear, J.
    Papadatos-Pastos, D.
    Ahmad, T.
    Chao, D.
    Asghar, U. S.
    Anand, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 620 - 620
  • [25] Angiogenesis and Immune-Related Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
    Grapsa, D.
    Papadopoulou, A.
    Kokkotou, E.
    Gaitanakis, S.
    Gkiozos, I.
    Charpidou, A.
    Syrigos, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S331 - S332
  • [26] Identification of immune-related gene signature for non-small cell lung cancer patients with immune checkpoint inhibitors
    Wang, Li
    Han, Chaonan
    Cai, Chenlei
    Wu, Jing
    Chen, Jianing
    Su, Chunxia
    HELIYON, 2024, 10 (05)
  • [27] Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer
    Romeo, Marzia Anita Lucia
    Garassino, Marina Chiara
    Moiola, Lucia
    Galli, Giulia
    Comi, Giancarlo
    Martinelli, Vittorio
    Filippi, Massimo
    JOURNAL OF NEUROLOGY, 2019, 266 (12) : 3163 - 3166
  • [28] Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study
    Zhang, Haoting
    Zheng, Jing
    Ren, Chenyi
    Ye, Chenlin
    Wu, Xiaoyu
    Lv, Xiaodong
    Li, Yuping
    Zhou, Jianya
    Zhou, Jianying
    BMC PULMONARY MEDICINE, 2025, 25 (01):
  • [29] Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer
    Marzia Anita Lucia Romeo
    Marina Chiara Garassino
    Lucia Moiola
    Giulia Galli
    Giancarlo Comi
    Vittorio Martinelli
    Massimo Filippi
    Journal of Neurology, 2019, 266 : 3163 - 3166
  • [30] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
12345